...consortium also includes BioSpring, which will provide miRNA synthesis services for the consortium; Dr. Reddy's OctoPlus N.V.... ...drug product formulations; and LPT, a GLP-accredited toxicology laboratory that provides testing and consulting services. OctoPlus...
...about 51.9 million shares, of OctoPlus. The companies are requesting NYSE Euronext Amsterdam to terminate OctoPlus'... ...or about €27.4 million ($36.1 million) (see BioCentury, Oct. 29, 2012 & Dec. 24, 2012). OctoPlus N.V....
...Dr. Reddy's began a tender offer to acquire drug delivery company OctoPlus for €0.52 per share... ...Reddy's said it held about 41.7 million shares, or about 79.2% (see BioCentury, Oct. 29). OctoPlus N.V....
...series A preferred stock and a warrant to purchase one common share, exercisable at $2. OctoPlus N.V.... ...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...the deal was announced. Dr. Reddy's will begin a tender offer in December. Last week, OctoPlus...
...Dr. Reddy's will acquire drug delivery company OctoPlus for €0.52 per share in cash, or about... ...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...year 2012 ending March 31, 2012. OctoPlus had 2011 revenues of €7.7 million ($10 million). OctoPlus N.V....
...Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) will acquire drug delivery company OctoPlus N.V. (Euronext:OCTO) for EUR 0.52 per... ...cash, or about EUR 27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...Friday, before the deal was announced. Dr. Reddy%27s will begin a tender offer in December. OctoPlus...
...consortium also includes BioSpring, which will provide miRNA synthesis services for the consortium; Dr. Reddy's OctoPlus N.V.... ...drug product formulations; and LPT, a GLP-accredited toxicology laboratory that provides testing and consulting services. OctoPlus...
...about 51.9 million shares, of OctoPlus. The companies are requesting NYSE Euronext Amsterdam to terminate OctoPlus'... ...or about €27.4 million ($36.1 million) (see BioCentury, Oct. 29, 2012 & Dec. 24, 2012). OctoPlus N.V....
...Dr. Reddy's began a tender offer to acquire drug delivery company OctoPlus for €0.52 per share... ...Reddy's said it held about 41.7 million shares, or about 79.2% (see BioCentury, Oct. 29). OctoPlus N.V....
...series A preferred stock and a warrant to purchase one common share, exercisable at $2. OctoPlus N.V.... ...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...the deal was announced. Dr. Reddy's will begin a tender offer in December. Last week, OctoPlus...
...Dr. Reddy's will acquire drug delivery company OctoPlus for €0.52 per share in cash, or about... ...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...year 2012 ending March 31, 2012. OctoPlus had 2011 revenues of €7.7 million ($10 million). OctoPlus N.V....
...Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) will acquire drug delivery company OctoPlus N.V. (Euronext:OCTO) for EUR 0.52 per... ...cash, or about EUR 27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'... ...Friday, before the deal was announced. Dr. Reddy%27s will begin a tender offer in December. OctoPlus...